SASKATOON, Saskatchewan — January 12, 2026 — Leads & Copy — ZYUS Life Sciences Corporation (TSXV: ZYUS) has launched a brokered private placement to raise a minimum of C$15 million and up to a maximum of C$16 million.
The clinical-stage life sciences company, which focuses on non-opioid drug candidates for pain management, is offering a minimum of 23,809,523 units and up to a maximum of 25,396,825 units at a price of C$0.63 per unit.
Each unit will consist of one common share of the company and one-half of one common share purchase warrant. Each whole warrant will allow the holder to purchase one additional common share at an exercise price of C$0.85 for 24 months from the date of issuance.
Canaccord Genuity Corp. is acting as the sole lead agent and sole bookrunner for the offering, on behalf of a syndicate of agents to be formed. The offering will be conducted on a best-efforts, fully marketed basis.
The company has agreed to pay the agents a cash commission of 5.0% of the gross proceeds from the offering, and to issue agents’ warrants equal to 5.0% of the number of units sold. Each agent’s warrant is exercisable for one common share at the offering price for 36 months from the date of issuance. Subscriptions from purchasers on the President’s List, up to a maximum of C$5,000,000, will be subject to reduced compensation of 2.5% cash commission and 2.5% agents’ warrants. The Lead Agent will also receive a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each case excluding President’s List subscriptions.
ZYUS intends to use the net proceeds to advance the clinical development of its lead drug candidate, Trichomylin® softgel capsules, including completion of its Phase 2a clinical trial and preparation for Phase 2b. The proceeds will also be used for working capital and general corporate purposes.
The units will be offered for sale to purchasers resident in all provinces of Canada other than Québec, pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions. The units may also be offered in the United States on a private placement basis and in other jurisdictions as may be agreed upon.
The units, along with the underlying common shares and warrants, will not be subject to a hold period pursuant to applicable Canadian securities laws. An offering document related to the offering can be accessed under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.zyus.com. Prospective investors should read the offering document before making an investment decision. Copies of the offering document may also be obtained from the Lead Agent at ECM@cgf.com.
The company’s common shares are listed on the TSX Venture Exchange under the symbol “ZYUS”. The offering is expected to close on or about January 29, 2026, subject to regulatory approvals, including approval of the TSXV.
ZYUS is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection and obtain regulatory approval of non-opioid-based pharmaceutical solutions.
ZYUS Media Inquiries can be contacted at media@zyus.com or 1-833-651-7723. ZYUS Investor Relations can be contacted at investors@zyus.com.
Source: ZYUS Life Sciences Corporation
